Pascal Hickey has watched a lot of children eat peanut protein under supervision: three or four nurses in the room, a crash cart in the corner, a chocolate matrix dosed in milligrams. The test is built to find the dose where a child's immune system breaks.
On 14 November the Aravax chief executive watched the results of that test get presented in Phoenix instead. PVX108, his company's peptide immunotherapy, met its Phase 2 primary endpoint in 71 children aged four to 11. The easy headline is another allergy breakthrough.
The real result is narrower. The safety profile is the finding. The efficacy is statistically solid and clinically modest, and the company's own framing — a platform that retrains T cells instead of flooding the body with peanut protein — is a claim about risk, not potency.
What the 2.4-fold number measures
Aravax ran AVX-201 across 14 sites in the US and Australia: a 24-adolescent safety cohort first, then 71 children aged four to 11 randomised to placebo, 5 nmol or 50 nmol of PVX108, injected intradermally once a month for 12 months.
The primary endpoint was the change in the largest dose of peanut a child could tolerate during a supervised food challenge. On the intent-to-treat set, the 50 nmol arm improved 2.4-fold on a least-squares geometric mean; placebo improved 1.2-fold. The gap was statistically significant, and 39.4% of the high-dose arm tolerated a cumulative 443 mg of peanut protein against 16.7% on placebo.
That 443 mg is the trial's proxy for a 300 mg maximum tolerated dose. One peanut carries roughly 250–300 mg of protein. Hickey's relevance benchmark is lower: the median amount that sends a peanut-allergic child to an emergency department with anaphylaxis is about 150 mg, he told Forbes Australia.
High-dose responders, intent-to-treat
Share of the 50 nmol arm tolerating at least 443 mg cumulative peanut protein at month 12, versus 16.7% on placebo. Aravax topline, November 2026
Mechanically, PVX108 belongs to a different product class from anything approved so far. It contains no whole peanut protein. Its peptides bind MHC II on antigen-presenting cells and are presented to T cells without the inflammatory co-signal that triggers IgE cross-linking, mast-cell degranulation and anaphylaxis. Monthly fixed dose, 0.6 mm needle, no escalation schedule.
That design shows up in the safety data. No treatment-related allergic adverse events, including anaphylaxis. No treatment-related serious adverse events. Treatment-related events in six children across all arms — one on placebo, two at 5 nmol, three at 50 nmol — none above grade 2, mostly injection-site reactions. Ninety-six per cent finished the 12 months, and nobody withdrew because of the drug.
This is the first study, to our knowledge, that has shown efficacy for a peanut-specific immunotherapy that doesn't contain peanut protein.— Pascal Hickey, chief executive, Aravax
The claim is narrower than it sounds. Peptides cannot cross-link IgE on mast cells, so the drug itself carries no anaphylaxis risk. Whether that translates into a product parents will actually keep in the fridge for a year is a different question, and one the extension study is designed to start answering.
The emotional toll of peanut allergy on children and their families is one of the greatest burdens of living with the condition.— Hickey, speaking to Healio at ACAAI
Six months after the last dose, a month-18 challenge showed tolerance maintained or improved. Fifty-nine of the 68 completers signed up for a 12-month open-label extension, with data due in the second half of 2027.
Aravax is not a new company. It spun out of Monash University in 2015 and now runs entities in Melbourne and Oxford. The trial began in February 2023, finished collecting primary data in September 2025 and will not formally close until mid-2028. That is eleven years from spin-out to a single positive Phase 2 readout — and still one trial removed from a registrational filing.
The comparison Aravax has to live with
Palforzia is the number every allergist will reach for. The only FDA-approved oral immunotherapy for peanut allergy, it got 67% of children to tolerate twice as much peanut — 600 mg — in its pivotal work. PVX108's headline responder rate covers a lower bar.
| Measure | Palforzia (peanut OIT) | PVX108 (peptide IT) |
|---|---|---|
| Dosing | Daily, with food | Monthly, intradermal |
| Tolerated dose reported | 67% reached 600 mg | 39.4% reached 300 mg |
| Treatment-related allergic events | Frequent; REMS restricted | None reported in Phase 2 |
| Status | Discontinued 31 July 2026 | Phase 3 planned |
Efficacy figures from Aravax and Forbes Australia reporting, November 2026; Palforzia status from Stallergenes Greer.
Then the harder part. Palforzia was discontinued on 31 July 2026. Its maker, Stallergenes Greer, pulled a product approved in 2020 and wrapped in a restrictive risk programme; Forbes reported Nestlé lost US$2.1 billion on it. The failure was commercial and tolerability-driven. Parents would not give it, clinicians would not prescribe it, adverse reactions were constant.
Four days later the FDA handed PVX108 Fast Track designation. That sequence is the bull case in one line: the only approved product in the category walked out, and the replacement candidate's main selling point is the thing the incumbent could not fix.
Twenty-three children on the high dose is a signal, not a rate you can bank.
The 2.4-fold is a geometric mean, and placebo moved 1.2-fold on its own — the incremental effect is closer to double than to 2.4×.
"Disease-modifying" rests on a single challenge six months off drug, not on years of follow-up.
What Phase 3 has to prove
The responder definition Aravax intends to take into Phase 3 is a 300 mg tolerated dose — the secondary endpoint that cleared statistical significance at the high dose. That is a deliberate choice. It sets the bar where accidental exposure sits, not where competitor marketing sits. It also means roughly six in ten treated children still miss it.
Scale is the next test. Phase 2 enrolled 95 people at 14 sites. A registrational programme will need hundreds, with adherence measured over years rather than a 12-month protocol. Monthly injections help there. So does a safety record with zero treatment-related allergic events, which no whole-protein immunotherapy has managed.
Money comes before medicine. Hickey puts the Phase 3 bill north of US$100 million (A$146 million); Aravax has raised a US$42 million Series B in total, from Novartis Venture Fund, Brandon Capital, Tenmile, Innovation Victoria, Uniseed and UniSuper. He is talking to strategic partners and says the company is prepared to run the trial alone if it has to. The peanut allergy treatment market is estimated near US$1.9 billion, with the wider food allergy market several times that. A single-asset company raising a nine-figure sum against a 39% responder rate is not a comfortable pitch.
There is a diagnostic wrinkle underneath the commercial one. Murdoch Children's Research Institute reported this month that 35% of 778 infants challenged across Australian hospitals did not react at all and had their peanut allergy diagnosis removed. Some share of the addressable population does not need immunotherapy. The rest need to be found, confirmed and referred — a care-pathway problem that no drug solves on its own.
Safety, not efficacy, is the differentiator: no treatment-related allergic events, monthly fixed dosing.
The next gate is financing north of US$100 million for a Phase 3 that must hold up in hundreds of children.
The field has a pattern we have watched before: efficacy wins announced at a conference, then a decade of manufacturing, adherence and reimbursement problems that quietly erase them. Palforzia was supposed to be a blockbuster and became a US$2.1 billion write-off. PVX108 inverts the usual risk profile by leading with safety. That inversion is the claim worth taking seriously.
What it is not yet is proof that a 39% responder rate survives contact with a few hundred children, real-world prescribing and a monthly injection schedule parents have to keep for a year. The open-label extension reports in late 2027; a Phase 3 start is the thing to date-stamp next. The same data will get a second airing at the EAACI meeting in Utrecht on 20 November, but a second presentation is not a second dataset.